Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

Abstract

Ixekizumab-treated patients achieved more rapid improvements both in HRQoL and itch compared with patients treated with ETN and PBO.

Medical needs and major complaints related to pruritus in Germany: a 4‐year retrospective analysis using Google AdWords Keyword Planner

“…Although a neglected area of medicine, recent studies have demonstrated the frequency and burden of psoriatic itch. 28,29 Interestingly, certain localizations were more prominent than others. Anal pruritus and pruritus of the scalp are especially problematic because there are few scientific findings in these issues.…”

“…Of the group of dermatoses, it is of interest that psoriasis was searched for as frequently as atopic dermatitis, once more supporting the role of pruritus in this disease. Although a neglected area of medicine, recent studies have demonstrated the frequency and burden of psoriatic itch . Interestingly, certain localizations were more prominent than others.…”

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

“…Moreover, the current analysis investigates the differential effects of two active treatments for moderate-to-severe psoriasis and the effects at different time points, which, to our knowledge, is rarely explored in SEM analyse. Leonardi and colleagues 26 focused on the effects of pruritus severity only, whereas the present study integrated three bothersome psoriasis-related symptoms and their interactions. 12,13 The confirmation of the hypothesis that the symptoms and feelings subscale was antecedent to a latent variable (factor) representing the remaining five subscales of the DLQI Total (revised) was a notable result of this analysis.…”

“…Moreover, the current analysis investigates the differential effects of two active treatments for moderate‐to‐severe psoriasis and the effects at different time points, which, to our knowledge, is rarely explored in SEM analyse. Leonardi and colleagues focused on the effects of pruritus severity only, whereas the present study integrated three bothersome psoriasis‐related symptoms and their interactions …”

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

“…Within 1 year of treatment, up to 80% of patients treated with IL‐17 or IL‐23 inhibitors can expect almost clear skin, as indicated by a 90% improvement in Psoriasis Area and Severity Index (PASI 90), and 50–60% of patients can expect completely clear skin (PASI 100) . Although clinical trial data and systemic reviews have suggested that IL‐17 inhibitors can improve a patient's psoriasis more rapidly than IL‐23 inhibitors, no trials have directly tested the speed of efficacy of IL‐17 vs. IL‐23 inhibitors in inducing complete plaque psoriasis clearance.…”